Italia Markets close in 2 hrs 46 mins

Grifols, S.A. (GRF.MC)

MCE - MCE Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
12,49-0,02 (-0,16%)
Al 02:21PM CEST. Mercato aperto.
Schermo intero
Chiusura precedente12,52
Denaro12,51 x 0
Lettera12,52 x 0
Min-Max giorno12,39 - 12,56
Intervallo di 52 settimane7,82 - 14,99
Media Volume1.027.847
Beta (5 anni mensile)0,46
Rapporto PE (ttm)73,50
EPS (ttm)0,17
Prossima data utili02 nov 2023
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendo03 giu 2021
Stima target 1A18,71
  • GlobeNewswire

    Grifols Accelerates Healthcare Innovation with Google Cloud’s AI and Analytics

    Grifols will apply artificial intelligence technologies, including large language models, to speed up the development of new biopharma therapeuticsAgreement is latest Grifols initiative to reinforce the robustness of its therapeutic pipeline and strengthen its innovation culture BARCELONA, Spain, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines that has been enhancing people’s health and

  • GlobeNewswire

    Grifols Achieves Positive Topline Results From Phase 4 Study of XEMBIFY® (immune globulin subcutaneous human-klhw) Evaluating Biweekly Dosing Option for Patients

    Clinical trial met primary endpoint demonstrating comparable total immunoglobulin (Ig) levels when administering XEMBIFY® (Grifols’ subcutaneous Ig) every two weeks, compared with weekly, in patients with primary immunodeficienciesStudy designed to support extending U.S. Food and Drug Administration labeling of XEMBIFY® to include biweekly dosing, providing added flexibility and convenience for patientsGrifols is accelerating adoption of XEMBIFY® as part of its broader immunoglobulin business st

  • GlobeNewswire

    Grifols Completes Enrollment in Phase 3 Study of Long-term Albutein® (albumin-human injection) Therapy for Patients with Decompensated Cirrhosis

    PRECIOSA clinical trial is designed to evaluate efficacy and safety of Grifols Albutein® plus standard medical treatment to increase survival time in patients with decompensated cirrhosis awaiting transplantAlbumin’s antioxidant and anti-inflammatory properties have the potential to mitigate the complications associated with decompensated cirrhosisGrifols continues innovating across its plasma-protein franchise and is committed to applying its ever-growing expertise in a range of therapeutic are